Rutgers–Camden Finest is an assembly of graduates whose lives and careers have made an indelible mark upon society and the advancement of knowledge.
Co-Founder and Managing Partner, NeXeption, LLC
Stephen Tullman’s career spans more than 25 years of biopharmaceutical global commercialization and drug development experience. He serves as the co-founder and managing partner for NeXeption, LLC, and co-founder and chair of Aclaris Therapeutics.
He was chair and CEO of Ceptaris Therapeutics (acquired by Actelion in 2013); co-founder and chair of Vicept Therapeutics (acquired by Allergan in 2011); co-founder, president, and CEO of Ception Therapeutics (acquired by Cephalon in 2010); and co-founder of Trigenesis Therapeutics, a dermatology company (acquired by Reddy's Laboratories in 2004).
He also served on the Board of Directors for Euromed, a wound care company. Tullman started his career at SmithKline Beecham and held positions of increasing responsibility in finance, sales, marketing, and research and development.